Timolol 0.5% / Brimonidine Tartrate 0.2% / Dorzolamide 2% / Bimatoprost 0.01% Preservative-Free Ophthalmic Solution

Timolol 0.5% / Brimonidine Tartrate 0.2% / Dorzolamide 2% / Bimatoprost 0.01% Preservative-Free Ophthalmic Solution

TIMolol 0.5%BRIMonidine Tartrate 0.2%DORZolamide 2%Bimatoprost 0.01% PF Ophthalmic Solution

Quantity: 8 mL

Price: Call 833.540.3500 or login to the Practitioner Portal for pricing.


Sterile compounded ophthalmic preparation available by prescription. The FDA does not review any compounded medication for safety or efficacy. 

What is Timolol / Brimonidine / Dorzolamide / Bimatoprost Ophthalmic Solution?

This is a compounded preservative-free ophthalmic solution containing:

  • Timolol 0.5% – beta-blocker
  • Brimonidine tartrate 0.2% – alpha-2 adrenergic agonist
  • Dorzolamide 2% – carbonic anhydrase inhibitor
  • Bimatoprost 0.01% – prostaglandin analog

Each agent contributes to intraocular pressure reduction through a different mechanism. In clinical practice, multi-drug therapy is often required when single or dual agents do not achieve adequate IOP control.

Compounding allows these medications to be combined into a single, preservative-free formulation, simplifying complex regimens.

What is the Mechanism of Action?

Each component reduces IOP through a distinct pathway:

  • Timolol
    • Decreases aqueous humor production via beta-receptor blockade
  • Brimonidine
    • Reduces aqueous production
    • Increases uveoscleral outflow
  • Dorzolamide
    • Inhibits carbonic anhydrase
    • Reduces fluid production in the ciliary body
  • Bimatoprost
    • Increases uveoscleral outflow
    • Enhances aqueous humor drainage

Together, these mechanisms provide a comprehensive, multi-pathway approach to lowering intraocular pressure.

Clinical Scenarios Where Ophthalmologists Explore This Combination

Ophthalmologists may consider this compounded formulation in scenarios such as:

  • Advanced or difficult-to-control glaucoma
  • Ocular hypertension not at goal with multiple agents
  • Patients already prescribed multiple separate drops
  • Situations where adherence is a concern, and regimen simplification may help
  • Patients intolerant to preservatives in commercial products
  • Cases requiring maximum topical therapy prior to procedural intervention

Use is determined by the treating ophthalmologist based on disease severity, target IOP, and patient-specific factors.

Why Ophthalmologists Choose Massey Drugs

  • Sterile compounding laboratory experienced in ophthalmic preparations
  • Preservative-free formulations tailored for ocular use
  • Direct pharmacist access for clinical questions
  • Fast turnaround with patient shipment typically within 24–48 hours
  • Experience working with corneal specialists and surgical practices
  • NABP Accredited Compounding Pharmacy

States We Serve

States where Massey Drugs ships compounded medications.

Massey Drugs is a sterile ophthalmic compounding pharmacy licensed to ship ophthalmic solutions to patients in: Alabama, Tennessee, Mississippi, Louisiana, Georgia, Florida, North Carolina, South Carolina, Kentucky, Illinois, Indiana, Ohio, Pennsylvania, New York, Connecticut, and Texas.

How to Prescribe Timolol / Brimonidine / Dorzolamide / Bimatoprost Ophthalmic Solution

Download Rx Blank from the Practitioner Portal and send to Massey Drugs:

FAX: 800.637.2601
Phone: 833.540.3500
OR

e-Scribe: NPI#: 1295756245 | NCPCP#: 0127553
Massey Drugs | Cloverdale Road 

Upon receipt of prescription, Massey Drugs contacts the patient to confirm shipping address and credit card payment. 

Medication ships to patient in 24-48 hours once processed.

Massey Drugs provides competitively priced compounded ophthalmic eye drops with transparent, prescriber-accessible pricing. All compound pricing can be viewed in our Practitioner Portal so costs can be communicated to patients before prescribing.

Speak with a Pharmacist

If you have questions about ophthalmic compounding, formulation options, or whether this therapy may be appropriate for a specific clinical scenario, our pharmacists are available to consult. Call 833-540-3500 or contact us.

Frequentley Asked Questions

When would a four-drug combination be considered in glaucoma management?

This type of combination may be considered in patients with advanced disease or persistently elevated IOP despite multi-drug therapy, where additional pressure reduction is needed.

A single formulation may reduce drop burden, dosing complexity, and timing errors, which can be challenges in patients managing multiple medications.

Yes. Providers may evaluate patients with respiratory conditions (e.g., asthma, COPD) or certain cardiac conditions, as beta-blockers can have systemic effects.

Additional Ophthalmic Compounding Capabilities

We compound additional sterile ophthalmic therapies used for: 

  • Post-operative Care
  • Emergency & Infection Management
  • Emergency & Corneal Scarring Support
  • Glaucoma Compounding
  • Myopia Management

Explore our full range of ophthalmic compounding capabilities.